Bitome
Bitome is a Boston-based, early-stage medical device startup founded in 2016 that develops noninvasive diagnostic tools for real-time patient volume status monitoring.
- Company typePublic
- Founded2008
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bitome does
Bitome is a Boston-based, privately held medical device startup founded in 2016 that develops noninvasive diagnostic tools for real-time volume status monitoring. The company operates with a small team (1-10 employees) and is headquartered in the United States, placing it firmly in the early-stage category of the patient monitoring diagnostics segment. Real-time volume status measurement is clinically relevant in conditions such as heart failure, kidney disease, sepsis, and critical care, where accurate fluid balance assessment influences treatment decisions.
The company's core offering is positioned at the intersection of noninvasive sensing and clinical diagnostics, addressing the need for continuous, bedside volume status data without invasive catheterization. Bitome does not publicly disclose its underlying sensor modality, device specifications, regulatory pathway, or clinical validation status in the available data; consequently the technological architecture (e.g., bioimpedance, optical, RF, or other sensing approach) cannot be specified from the input.
Bitome's commercial business model is not detailed in the available data—there are no disclosed customers, pricing, distribution channels, or revenue figures. Capital sources include a $225,000 award from the National Science Foundation in May 2020 and a multi-year engagement with the SOSV HAX hardware accelerator spanning 2016 through 2018, consistent with a hardware-led medical device development trajectory. Trevor Kemp is identified as co-founder. No management team beyond the co-founder role is disclosed, and no board, advisory, or partnership relationships are documented.
Bitome firmographics
Firmographics- Name
- Bitome
- Legal name
- Ginkgo Bioworks
- Website
- https://bitome.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bitome is a Boston-based, early-stage medical device startup founded in 2016 that develops noninvasive diagnostic tools for real-time patient volume status monitoring.
- Ownership category
- akta.pro rank
Bitome industry classification
Industry- Product category
- Medical Diagnostics
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
- akta.pro secondary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
Keywords
Where Bitome is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Bitome business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Autonomous Lab Build-Out Services: Building proprietary autonomous labs at customer sites (e.g., Boston HQ). Customers gain dedicated robotic lab infrastructure tailored to their R&D needs.
- Cloud Lab Access: On-demand access to Ginkgo's autonomous lab in Boston for running experiments. Ginkgo Solutions and Ginkgo Datapoints teams design and execute experiments addressing customer project goals.
- AI & Data Services: Specialized AI-driven services including antibody developability assessment, perturbation response profiling, small molecule developability, and high-throughput screening.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Bitome product offering
Product offeringCore offering
Bitome develops noninvasive diagnostic (Dx) tools for real-time volume status monitoring. The company's product is targeted at clinical settings where continuous, contactless assessment of patient fluid/volume status is needed, eliminating the need for invasive monitoring approaches.
Product overview
Ginkgo Bioworks offers an autonomous laboratories platform for biotechnology. The core offering includes Cloud Lab (robotic lab infrastructure in Boston), the Catalyst Agent AI system for automating experimental workflows, and Ginkgo Datapoints for AI-powered data analysis services. Customers can either build their own autonomous labs using Ginkgo's hardware/software products or access Ginkgo's existing lab through the Cloud Lab service. Additional offerings include Ginkgo Solutions (custom R&D project support), Ginkgo Reagents (lab supplies), and sub-brands Grow by Ginkgo (consumer applications) and Ginkgo Ferment (fermentation services). The company serves over 130 customers including major pharmaceutical and biotechnology companies.
Differentiator
Problem solved
Functional benefit
Brands
- Ginkgo Datapoints: AI-powered data services platform offering antibody developability, perturbation response profiling, small molecule developability, and specialized high-throughput screening services.
- Ginkgo Ferment
- Grow by Ginkgo
- Ginkgo Reagents
- Cloud Lab
Products and services
- Noninvasive Volume Status Diagnostic Tool
Quantifiable outcome
- 130+ customers utilizing autonomous lab services
Companies that use Bitome
Customer profileNamed customers10 records
Segments2 records
Ideal customer profiles1 record
Bitome technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Bitome partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights2 records
Bitome competitors and assessment
Company assessmentBroad incumbents
- GE HealthCare: GE HealthCare's patient-monitoring ecosystem (including its ICU and ambulatory monitoring lines) embeds hemodynamic and vital-sign parameters into a broader hospital platform — directly competing for the same procurement and clinical-decision-support mindshare.
- Medtronic: Medtronic's broader cardiac diagnostics and patient-monitoring franchise (including heart failure diagnostics and LINQ ICM) competes for the same clinical and economic buyer (cardiologists, hospital systems) that would adopt a noninvasive fluid-monitoring solution.
- Abbott: Abbott's CardioMEMS HF System is an established remote pulmonary-artery-pressure monitoring solution for heart failure — addressing the same underlying clinical need as Bitome but via an implantable rather than noninvasive modality.
- Baxter: Baxter's fluid-management and patient-monitoring portfolio (including IV infusion and Starling fluid-management technologies) targets the same clinical workflow of inpatient fluid-balance optimization that Bitome addresses.
- Edwards Lifesciences: Edwards' FloTrac/Vigileo and ClearSight systems provide continuous, less-invasive hemodynamic monitoring — overlapping with Bitome's positioning as a noninvasive alternative for ICU and perioperative volume-status assessment.
- Philips: Philips' continuous patient-monitoring and connected-care portfolio (IntelliVue, wearable biosensor solutions) competes in both hospital and ambulatory fluid/vital-sign monitoring use cases that Bitome targets.
Direct peers
- Masimo: Masimo's continuous patient-monitoring portfolio (including the ViSi Mobile system via its Sotera Wireless acquisition) provides real-time, noninvasive vital-sign and hemodynamic data in hospital and ambulatory settings — directly comparable to Bitome's real-time noninvasive volume-status monitoring value proposition.
- CNOGA Medical: CNOGA develops noninvasive hemodynamic and vital-sign monitoring devices that compute parameters such as cardiac output and fluid status from optical sensor inputs — a closely analogous approach to Bitome's noninvasive volume-status focus.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Bitome social profiles
Digital presenceBitome financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bitome leadership team
Management profileNumber of profiles
Profiles1 record
Bitome subsidiaries and ownership
Company hierarchySubsidiaries5 records
Bitome funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bitome M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bitome
What does Bitome do?
Bitome develops noninvasive diagnostic (Dx) tools for real-time volume status monitoring. The company's product is targeted at clinical settings where continuous, contactless assessment of patient fluid/volume status is needed, eliminating the need for invasive monitoring approaches.
Is Bitome a public or private company?
Bitome is a public company. It is classified as venture growth investor backed and is currently operating.
When was Bitome founded?
Bitome was founded in 2008. It employs 1 to 10 people.
Where is Bitome based?
Bitome is headquartered in Boston, United States, in the North America region.
How does Bitome make money?
Three revenue lines are on record. Autonomous Lab Build-Out Services are the primary driver. The others are cloud Lab Access and AI & Data Services.
Who are Bitome's main competitors?
Broad incumbents on record are GE HealthCare, Medtronic, Abbott, Baxter, Edwards Lifesciences and Philips. Direct peers are Masimo and CNOGA Medical.
Does Bitome have an API?
No public API is recorded for Bitome.
What industry is Bitome in?
Bitome's product category is Medical Diagnostics. Its primary akta.pro industry code is HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 3391 and its SIC code is 3841.